Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people
KEYWORDS: ethyl, icosapent, icosapent ethyl, treatment, company, cardiovascular, people, committee, effect, treatment effect, model, events, noted, reduce-it, clinical

of publication. 4.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final appraisal document. 4.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has raised triglycerides and the doctor responsible for their care thinks that icosapent ethyl is the right treatment to reduce the risk of cardiovascular events, it should be available for use, in line with NICE's recommendations.
